Arthrosi
San Diego, US · 1 known investors
Arthrosi Therapeutics is a clinical-stage biotech company developing AR882 (pozdeutinurad), a urate-lowering drug candidate for gout, tophaceous gout, and chronic kidney disease. The company is running Phase 3 trials for its treatment aimed at patients with gout, including those with tophi and chronic refractory gout.
BiotechDigital Health